Quarterly report · Q1
4543.TEDINET S100OZIL
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥197.3bn | 2022-04-01 → 2022-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥171.7bn | 2021-04-01 → 2021-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥30.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥36.2bn | 2021-04-01 → 2021-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥29.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥36.0bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥27.9bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥22.4bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥27.9bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.58T | at 2022-06-30 | Cons. | Assets IFRS |
| Total assets | ¥1.47T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.34T | at 2021-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥466.9bn | at 2022-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥461.4bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.12T | at 2022-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥874.0bn | at 2021-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥856.7bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.12T | at 2022-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.01T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥874.0bn | at 2021-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥209.6bn | at 2022-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥186.7bn | at 2021-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥200.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥23.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥29.9bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥16.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥21.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥14.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥23.1bn | 2021-04-01 → 2021-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥29.61 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥117.45 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥36.9 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥29.6 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥117.38 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥36.87 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 70.5% | at 2022-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 65.2% | at 2021-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-06-30 | ¥62m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥198m |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥34.5bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥3.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥116.8bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥28.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥46.0bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥4.5bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥197.3bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥36.1bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-06-30 | ¥64m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥1.6bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥28.3bn |
| jpcrp040300-q1r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥6.0bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥99.6bn |
| jpcrp040300-q1r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥29.4bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥43.8bn |
| jpcrp040300-q1r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥6.4bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥171.7bn |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥41.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 562
| Item | Context | Value | Unit |
|---|---|---|---|
| Equity IFRS | CurrentQuarterInstant_OtherComponentsOfEquityIFRSMember | 176294000000 | JPY |
| Equity IFRS | CurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember | 1116514000000 | JPY |
| Equity IFRS | CurrentQuarterInstant | 1116514000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 36020000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 29667000000 | JPY |
| Depreciation and amortization ope cf IFRS | Prior1YTDDuration | 13946000000 | JPY |
| Depreciation and amortization ope cf IFRS | CurrentYTDDuration | 16612000000 | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | Prior1YTDDuration | － | JPY |
| Impairment losses reversal of impairment losses ope cf IFRS | CurrentYTDDuration | 1699000000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | Prior1YTDDuration | -33000000 | JPY |
| Share of loss profit of investments accounted for using equity method ope cf IFRS | CurrentYTDDuration | 10000000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | Prior1YTDDuration | 904000000 | JPY |
| Increase or decrease in retirement benefit asset or liability ope cf IFRS | CurrentYTDDuration | 811000000 | JPY |
| Interest and dividend income ope cf IFRS | Prior1YTDDuration | -179000000 | JPY |
| Interest and dividend income ope cf IFRS | CurrentYTDDuration | -259000000 | JPY |
| Interest expenses ope cf IFRS | Prior1YTDDuration | 332000000 | JPY |
| Interest expenses ope cf IFRS | CurrentYTDDuration | 767000000 | JPY |
| Foreign exchange loss gain ope cf IFRS | Prior1YTDDuration | 190000000 | JPY |
| Foreign exchange loss gain ope cf IFRS | CurrentYTDDuration | 2313000000 | JPY |
| Loss gain on sale and retirement of fixed assets ope cf IFRS | Prior1YTDDuration | 26000000 | JPY |
| Loss gain on sale and retirement of fixed assets ope cf IFRS | CurrentYTDDuration | -17000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | Prior1YTDDuration | 3031000000 | JPY |
| Decrease increase in trade and other receivables ope cf IFRS | CurrentYTDDuration | 1305000000 | JPY |
| Decrease increase in inventories ope cf IFRS | Prior1YTDDuration | -2336000000 | JPY |
| Decrease increase in inventories ope cf IFRS | CurrentYTDDuration | -4545000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | Prior1YTDDuration | -4777000000 | JPY |
| Increase decrease in trade and other payables ope cf IFRS | CurrentYTDDuration | -4050000000 | JPY |
| Other changes in working capital ope cf IFRS | Prior1YTDDuration | -6049000000 | JPY |
| Other changes in working capital ope cf IFRS | CurrentYTDDuration | -11262000000 | JPY |
| Subtotal ope cf IFRS | Prior1YTDDuration | 41074000000 | JPY |
| Subtotal ope cf IFRS | CurrentYTDDuration | 33052000000 | JPY |
| Interest and dividends received ope cf IFRS | Prior1YTDDuration | 434000000 | JPY |
| Interest and dividends received ope cf IFRS | CurrentYTDDuration | 792000000 | JPY |
| Interest paid ope cf IFRS | Prior1YTDDuration | -608000000 | JPY |
| Interest paid ope cf IFRS | CurrentYTDDuration | -543000000 | JPY |
| Income taxes refund paid ope cf IFRS | Prior1YTDDuration | -10996000000 | JPY |
| Income taxes refund paid ope cf IFRS | CurrentYTDDuration | -9940000000 | JPY |
| Net cash provided by used in operating activities IFRS | Prior1YTDDuration | 29904000000 | JPY |
| Net cash provided by used in operating activities IFRS | CurrentYTDDuration | 23361000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | Prior1YTDDuration | -14073000000 | JPY |
| Purchase of property plant and equipment inv cf IFRS | CurrentYTDDuration | -11523000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | Prior1YTDDuration | 1000000 | JPY |
| Proceeds from sale of property plant and equipment inv cf IFRS | CurrentYTDDuration | 48000000 | JPY |
| Purchase of intangible assets inv cf IFRS | Prior1YTDDuration | -5878000000 | JPY |
| Purchase of intangible assets inv cf IFRS | CurrentYTDDuration | -4195000000 | JPY |
| Purchase of marketable securities inv cf IFRS | Prior1YTDDuration | -353000000 | JPY |
| Purchase of marketable securities inv cf IFRS | CurrentYTDDuration | -394000000 | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | Prior1YTDDuration | － | JPY |
| Proceeds from sale of marketable securities inv cf IFRS | CurrentYTDDuration | 78000000 | JPY |
| Payments for acquisition of subsidiaries inv cf IFRS | Prior1YTDDuration | -719000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |